Does Mounjaro specifically target fat, or does it reduce all body mass?

The real question: is the weight coming from fat or from muscle?

When people ask whether Mounjaro targets fat, they are usually weighing up something specific: will this treatment shrink my waistline, or will it just make me lighter in a way that leaves me weaker? It is a fair concern. Any significant calorie restriction can cause the body to break down lean tissue alongside fat, particularly if protein intake drops and activity levels fall.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed nearly 2,539 adults with obesity over 72 weeks. At the 15mg dose, average body-weight reduction reached around 20–21%. Body composition analyses from the programme showed that the large majority of that reduction was adipose (fat) mass, with lean mass losses considerably smaller in proportion. That does not happen automatically: it reflects what tends to occur when appetite falls gradually, calorie intake reduces moderately rather than drastically, and participants continue to move.

Tirzepatide's dual mechanism matters here. GIP receptor activation has specific effects on fat cell metabolism that GLP-1 activation alone does not produce, which is one reason researchers believe the body-composition profile of tirzepatide may differ from single-pathway medicines. The evidence is still accumulating, and individual results vary, but the direction the data points is encouraging for people who want to lose fat without losing function.

What tirzepatide actually does inside the body

Tirzepatide does not seek out belly fat or visceral deposits in the way a targeted drug might. What it does is create the hormonal conditions in which your body has less incentive to store energy and more reason to draw on what is already there. By mimicking GIP and GLP-1, it signals to the brain that you are full sooner, slows the rate at which the stomach empties, and reduces the drive to eat between meals.

The consequence is a reliable, sustained calorie deficit, something notoriously hard to maintain through willpower alone because hunger hormones typically fight back against restriction. Tirzepatide quietens that counter-signal. The body then metabolises stored fat to meet its energy needs, which is exactly the process behind the weight loss seen in trials.

If you are curious about the specific mechanisms at a cellular level, our page on how Mounjaro burns fat goes into more detail on what happens once that deficit is established. For a broader look at the science, the tirzepatide overview covers the dual-receptor mechanism in full.

One point worth knowing: visceral fat (the metabolically active fat around the organs) tends to be preferentially mobilised during weight loss compared with subcutaneous fat. That pattern holds for tirzepatide-assisted weight loss too, though the degree varies between individuals.

What you can do to keep the loss in fat, not muscle

Tirzepatide creates the conditions; your habits shape the composition of what you lose. Three things make the biggest practical difference. First, protein: appetite falls significantly on treatment, and it is easy to under-eat protein without noticing. Prioritising it at each meal (eggs, fish, meat, legumes, Greek yoghurt) helps the body preserve muscle while running on fat stores. Second, resistance exercise: even two sessions a week of bodyweight or weight-bearing activity signals to the body that lean tissue is needed. Third, hydration: GI side effects, particularly early on, can reduce fluid intake; staying well hydrated supports both metabolism and kidney function.

The NHS patient information for tirzepatide notes the importance of a reduced-calorie diet and increased physical activity alongside treatment, the medicine works best as part of that picture, not instead of it. Your prescriber and, where appropriate, a dietitian can tailor the detail to your starting point.

For context on how body-fat loss with tirzepatide compares across different doses and time points, the Mounjaro fat loss page brings together the evidence. And if the question of belly fat specifically is on your mind, whether Mounjaro reduces belly fat addresses the visceral-fat evidence directly.

Deciding whether this is the right medicine for your situation

Body composition matters, but it is one factor among several a prescriber considers. Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone is not the whole picture, the prescriber looks at your full health history, current medicines, and any contraindications before deciding whether tirzepatide is appropriate.

Some people ask about cost at this stage, which is reasonable. Our guide to Mounjaro pricing in the UK explains what legitimate private treatment includes and why headline prices sometimes leave things out. Mounjaro is a prescription medicine, so cost has to be weighed alongside clinical suitability and supply-chain assurance.

Treatment starts at the 2.5mg dose, a tolerability step that lets the body adjust before the prescriber considers moving up. The titration that follows is a clinical decision, not a fixed schedule, and depends on how you respond. If you ever miss a dose, our prescribers' advice on what to do if you forget Mounjaro is worth reading before that situation arises, better to know the answer on a quiet Tuesday than to be searching during a busy holiday week.

If you would like to discuss your situation with a prescriber, you can start your free consultation with our clinical team. A named GPhC-registered prescriber reviews every consultation personally.